105 related articles for article (PubMed ID: 19746677)
1. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
Hwang TJ; Dotsenko S; Jafarov A; Weyer K; Falzon D; Lunte K; Nunn P; Jaramillo E; Keshavjee S; Wares DF
BMJ Open; 2014 Jan; 4(1):e004143. PubMed ID: 24384902
[TBL] [Abstract][Full Text] [Related]
2. Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study.
Nogueira AS; Garcia MAC; Silva MBD; Costa PFD; Frade MAC; Salgado CG; Barreto JG
Trop Med Int Health; 2024 Apr; 29(4):327-333. PubMed ID: 38348585
[TBL] [Abstract][Full Text] [Related]
3. Clofazimine-induced skin pigmentation.
Karnan A; Ledwani A
Pan Afr Med J; 2024; 47():86. PubMed ID: 38737223
[No Abstract] [Full Text] [Related]
4. Clofazimine-associated enteropathy.
Zhang J; Dong J
Gastrointest Endosc; 2024 Jun; 99(6):1070-1071. PubMed ID: 38302070
[No Abstract] [Full Text] [Related]
5. Clofazimine: a review of its medical uses and mechanisms of action.
Arbiser JL; Moschella SL
J Am Acad Dermatol; 1995 Feb; 32(2 Pt 1):241-7. PubMed ID: 7829710
[TBL] [Abstract][Full Text] [Related]
6. Clofazimine-induced ichthyosis and its treatment.
Caver CV
Cutis; 1982 Apr; 29(4):341-3. PubMed ID: 7083909
[TBL] [Abstract][Full Text] [Related]
7. Zinc therapy in dermatology: a review.
Gupta M; Mahajan VK; Mehta KS; Chauhan PS
Dermatol Res Pract; 2014; 2014():709152. PubMed ID: 25120566
[TBL] [Abstract][Full Text] [Related]
8. Acantholytic cells in pemphigus. A scanning and transmission electron microscopic study.
Hietanen J
Acta Odontol Scand; 1982; 40(5):257-73. PubMed ID: 6960626
[TBL] [Abstract][Full Text] [Related]
9. Clofazimine for the treatment of tuberculosis.
Stadler JAM; Maartens G; Meintjes G; Wasserman S
Front Pharmacol; 2023; 14():1100488. PubMed ID: 36817137
[TBL] [Abstract][Full Text] [Related]
10. Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche.
McGuffin SA; Pottinger PS; Harnisch JP
Open Forum Infect Dis; 2017; 4(3):ofx147. PubMed ID: 30202770
[TBL] [Abstract][Full Text] [Related]
11. State-dependent blocking mechanism of Kv 1.3 channels by the antimycobacterial drug clofazimine.
Faouzi M; Starkus J; Penner R
Br J Pharmacol; 2015 Nov; 172(21):5161-73. PubMed ID: 26276903
[TBL] [Abstract][Full Text] [Related]
12. Use of clofazimine in dermatology.
Gurfinkel P; Pina JC; Ramos-e-Silva M
J Drugs Dermatol; 2009 Sep; 8(9):846-51. PubMed ID: 19746677
[TBL] [Abstract][Full Text] [Related]
13. Clofazimine should be used in all cases of leprosy, says Indian research council.
Bhaumik S
BMJ; 2013 Mar; 346():f1963. PubMed ID: 23533127
[No Abstract] [Full Text] [Related]
14. Laryngeal sarcoidosis: treatment with the antileprosy drug clofazimine.
Ridder GJ; Strohhäcker H; Löhle E; Golz A; Fradis M
Ann Otol Rhinol Laryngol; 2000 Dec; 109(12 Pt 1):1146-9. PubMed ID: 11130828
[TBL] [Abstract][Full Text] [Related]
15. Photosensitisation induced by clofazimine in a cat.
Bennett Sl
Aust Vet J; 2007 Sep; 85(9):375-80. PubMed ID: 17760943
[TBL] [Abstract][Full Text] [Related]
16. The pharmacology, metabolism, and chemistry of clofazimine.
O'Connor R; O'Sullivan JF; O'Kennedy R
Drug Metab Rev; 1995; 27(4):591-614. PubMed ID: 8925720
[No Abstract] [Full Text] [Related]
17. Innovative uses of thalidomide.
Chen M; Doherty SD; Hsu S
Dermatol Clin; 2010 Jul; 28(3):577-86. PubMed ID: 20510766
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
